NCT04770246: TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PTEN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with germline (hereditary) PTEN inactivating mutations determined from a blood sample are eligible for phase 2 of the study
Exclusions: Patients with prior treatment of PI3K/AKT/mTOR pathway inhibitor (e.g. alpelisib/Piqray, everolimus/Afinitor); Patients with leptomeningeal disease or symptomatic, unstable brain metastasis

Comments are closed.

Up ↑